• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 7:15:10 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRX alert in real time by email
    8-K
    false000178332800017833282025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported)

    May 6, 2025

     

    TSCAN THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-40603

    82-5282075

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    830 Winter Street

     

    Waltham, Massachusetts

     

    02451

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code

    857 399-9500

     

    Not Applicable

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Voting Common Stock, par value $0.0001 per share

     

    TCRX

     

    The Nasdaq Global Market, LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

    Exhibit No.

    Description

    99.1

    Press Release issued by TScan Therapeutics, Inc., dated May 6, 2025.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    TScan Therapeutics, Inc.

     

     

     

     

    Date:

    March 6, 2025

    By:

    /s/ Gavin MacBeath

     

     

     

    Gavin MacBeath, Ph.D
    Chief Executive Officer
    (Principal Executive Officer)

     

     

     

     


    Get the next $TCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRX

    DatePrice TargetRatingAnalyst
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    8/10/2021$21.00Buy
    Jefferies
    More analyst ratings